Preventing oxaliplatin-induced neurotoxicity: rationale and design of phase Ib randomized, double-blind, placebo-controlled, cross-over trials for early clinical evaluation of investigational therapeutics

References

• Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon Cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–3116.
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–2947.
   PubMed Web of Science ®Google Scholar
• Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465–1471.
   PubMed Web of Science ®Google Scholar
• Kuebler JP, Wieand HS, O’Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25:2198–2204.
   PubMed Web of Science ®Google Scholar
• Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol. 2003;21:2059–2069.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New England J Med. 2011;364:1817–1825.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. New England J Med. 2008;358:36–46.
   PubMed Web of Science ®Google Scholar
• Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol. 2003;30:5–13.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Cavaletti G, Briani C, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer. 2013;119:438–444.
   PubMed Web of Science ®Google Scholar
• Mols F, Beijers T, Lemmens V, et al. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol. 2013;31:2699–2707.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2014;32:1941–1967.
   PubMed Web of Science ®Google Scholar
• Majithia N, Temkin SM, Ruddy KJ, et al. National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons. Support Care Cancer. 2016;24:1439–1447.
   PubMed Web of Science ®Google Scholar
• Poupon L, Kerckhove N, Vein J, et al. Minimizing chemotherapy-induced peripheral neuropathy: preclinical and clinical development of new perspectives. Expert Opin Drug Saf. 2015;14:1269–1282.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Han CH, Khwaounjoo P, Kilfoyle DH, et al. Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients. BMC Cancer. 2013;13:495.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Qin R, Dakhil SR, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol. 2014;32:9997–1005.
   Web of Science ®Google Scholar
• Pachman DR, Qin R, Seisler DK, et al. clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance). J Clin Oncol. 2015;33:3416–3422.
   Google Scholar
• Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004;10:4055–4061.
   PubMed Web of Science ®Google Scholar
• Pachman DR, Ruddy K, Sangaralingham LR, et al. Calcium and magnesium use for oxaliplatin-induced neuropathy: a case study to assess how quickly evidence translates into practice. J Natl Compr Cancer Netw. 2015;13:1097–1101.
   PubMed Web of Science ®Google Scholar
• Graham MA, Lockwood GF, Greenslade D, et al. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000;6:1205–1218.
   PubMed Web of Science ®Google Scholar
• Jerremalm E, Wallin I, Ehrsson H. New insights into the biotransformation and pharmacokinetics of oxaliplatin. J Pharm Sci. 2009;98:3879–3885.
   PubMed Web of Science ®Google Scholar
• Jerremalm E, Wallin I, Yachnin J, et al. Oxaliplatin degradation in the presence of important biological sulphur-containing compounds and plasma ultrafiltrate. Eur J Pharm Sci. 2006;28:278–283.
   PubMed Web of Science ®Google Scholar
• Spingler B, Whittington DA, Lippard SJ. 2.4 angstrom crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex. Inorg Chem. 2001;40:5596–5602.
   PubMed Web of Science ®Google Scholar
• Machin D, Campbell M, Fayers P, et al. Sample size tables for clinical studies. Blackwell Sci. 1997;102–104.
   Google Scholar
• Balin-Gauthier D, Delord JP, Rochaix P, et al. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemother Pharmacol. 2006;57:709–718.
   PubMed Web of Science ®Google Scholar
• Ip V, Liu JJ, McKeage MJ. Evaluation of effects of copper histidine on copper transporter 1-mediated accumulation of platinum and oxaliplatin-induced neurotoxicity in vitro and in vivo. Clin Exp Pharmacol Physiol. 2013;40:371–378.
   PubMed Web of Science ®Google Scholar
• Louvet C, Coudray AM, Tournigand C, et al. Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude mice. Anti-Cancer Drugs. 2000;11:579–582.
   PubMed Web of Science ®Google Scholar
• Hui D, Zhukovsky DS, Bruera E. Which treatment is better? Ascertaining patient preferences with crossover randomized controlled trials. J Pain Symptom Manage. 2015;49:625–631.
   PubMed Web of Science ®Google Scholar
• Louis TA, Lavori PW, Bailar JC, et al. Crossover and self-controlled designs in clinical research. N Engl J Med. 1984;310:24–31.
   PubMed Web of Science ®Google Scholar
• Mills EJ, Chan AW, Wu P, et al. Design, analysis, and presentation of crossover trials. Trials. 2009;10:27.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services Food and Drug Administration CfDEaRC. Statistical Approaches to Establishing Bioequivalence; 2001. Available from: http://www.fda.gov/downloads/Drugs/…/Guidances/ucm070244.pdf
   Google Scholar
• U.S. Department of Health and Human Services Food and Drug Administration CfDEaRC. Drug Interaction Studies —Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations; 2012. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf
   Google Scholar
• Gluud LL. Bias in clinical intervention research. Am J Epidemiol. 2006;163:493–501.
   PubMed Web of Science ®Google Scholar
• Ip V, McKeage MJ, Thompson P, et al. Platinum-specific detection and quantification of oxaliplatin and Pt(R, R-diaminocyclohexane)Cl(2) in the blood plasma of colorectal cancer patients. J Anal At Spectrom. 2008;23:881–884.
   Web of Science ®Google Scholar
• Hill A, Bergin P, Hanning F, et al. Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability. BMC Cancer. 2010;10:451–459.
   PubMed Web of Science ®Google Scholar
• McDonald JH. Handbook of biological statistics. Baltimore (MD): Sparky House Publishing; 2008.
   Google Scholar
• Zimmerman C, Atherton PJ, Pachman D, et al. MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Support Care Cancer. 2016;24:1071–1078.
   PubMed Web of Science ®Google Scholar
• Alejandro LM, Behrendt CE, Chen K, et al. Predicting acute and persistent neuropathy associated with oxaliplatin. Am J Clin Oncol. 2013;36:331–337.
   PubMed Web of Science ®Google Scholar
• Velasco R, Bruna J, Briani C, et al. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry. 2014;85:392–398.
   PubMed Web of Science ®Google Scholar